Last reviewed 2026-05-14 · How we verify

Flu Pandemic mRNA_Dose level 2

GlaxoSmithKline · Phase 1 active Biologic Quality 0/100

Flu Pandemic mRNA_Dose level 2 is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 1 development.

At a glance

Generic name	Flu Pandemic mRNA_Dose level 2
Sponsor	GlaxoSmithKline
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Flu Pandemic mRNA_Dose level 2 CI brief — competitive landscape report
Flu Pandemic mRNA_Dose level 2 updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI

Frequently asked questions about Flu Pandemic mRNA_Dose level 2

What is Flu Pandemic mRNA_Dose level 2?

Flu Pandemic mRNA_Dose level 2 is a Biologic drug developed by GlaxoSmithKline.

Who makes Flu Pandemic mRNA_Dose level 2?

Flu Pandemic mRNA_Dose level 2 is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What development phase is Flu Pandemic mRNA_Dose level 2 in?

Flu Pandemic mRNA_Dose level 2 is in Phase 1.

Manufacturer: GlaxoSmithKline — full pipeline
Compare: Flu Pandemic mRNA_Dose level 2 vs similar drugs
Pricing: Flu Pandemic mRNA_Dose level 2 cost, discount & access